Automated insulin delivery, often referred to as AID, represents one of the most significant advances in diabetes management in decades. If you've heard terms like "hybrid closed-loop," "artificial pancreas," or "smart pump" and weren't quite sure what they meant or whether they applied to you, this guide is designed to clear that up. AID systems aren't just for a narrow group of patients. They're becoming the standard of care for people with type 1 diabetes and are increasingly available for type 2 diabetes as well, and understanding how they work is the first step to knowing whether one might be right for you.
AID Systems at a Glance: The Key Concepts
A review published in PubMed Central describes an AID system as a combination of a real-time CGM feeding glucose data to an algorithm that adjusts insulin delivery via an insulin pump based on continuous glucose readings. The system is called "hybrid" closed-loop because users still initiate mealtime boluses manually. Here's the core framework:
- CGM: The sensor reads your glucose every few minutes and sends data to the pump's algorithm
- Algorithm: Software built into the pump that calculates how much insulin to deliver, increase, or reduce based on current and predicted glucose
- Pump: Delivers basal insulin automatically based on algorithm instructions, and delivers bolus insulin when you initiate it manually at meals
- Hybrid closed-loop: The current standard for most commercial AID systems. Basal insulin is automated; mealtime boluses still require user input
- Fully closed-loop: A newer category where the system handles mealtime insulin automatically with minimal or no user input. The Beta Bionics iLet approaches this with its meal announcement feature
Most people using an AID system spend the majority of their time in automated mode, meaning the system is constantly making small, frequent adjustments to keep glucose within a target range without manual intervention.
What Actually Happens When You're in Automated Mode
Understanding what an AID system is doing in the background makes it much easier to trust the technology and work with it effectively rather than fighting it.
Every few minutes, your CGM sends a glucose reading to the pump. The algorithm looks at that reading, recent glucose trends, and the insulin already active in your body (called insulin on board) and decides whether to increase, decrease, or pause basal insulin delivery. If glucose is trending upward, the system may increase delivery proactively. If glucose is dropping, it may reduce or suspend delivery to prevent a low.
According to a systematic review of commercial hybrid closed-loop systems published in PubMed Central, these systems consistently improve time in range and reduce concerns around severe hypoglycemia across multiple real-world and clinical trial settings. The review, which analyzed 59 studies covering the MiniMed 780G, Tandem Control-IQ, Omnipod 5, and other systems, found that hybrid closed-loop therapy is one of the most impactful interventions available for improving glycemic control in type 1 diabetes.
What this means practically is that AID systems tend to smooth out the glucose variability that causes some of the most frustrating and exhausting moments in diabetes management. Overnight control in particular improves significantly for many users because the system is working while you sleep, catching rises and falls without any action needed on your part.
Meals are still the area where the most user input is needed. In current hybrid closed-loop systems, announcing a meal and entering a carbohydrate estimate triggers a bolus that covers the expected glucose rise. The algorithm then monitors what happens after the meal and adjusts basal delivery accordingly. The more accurately meals are announced, the better the system can respond. That said, a real-world study published in PubMed Central found that the Omnipod 5 algorithm can deliver up to 38% of total daily insulin in response to a missed or underestimated meal bolus, which provides a meaningful safety buffer for imperfect inputs.
Current AID Systems: What's Available and How They Differ
All currently available AID systems share the same basic architecture: a CGM, a pump, and an algorithm. What differs is how each system's algorithm works, how it handles meals, what its automation targets are, and what CGMs it's compatible with.
The Tandem t:slim X2 with Control-IQ uses predictive technology to forecast glucose 30 minutes ahead and adjusts basal insulin and delivers automatic correction boluses when needed. It is compatible with the Dexcom G6, Dexcom G7, and FreeStyle Libre 2/3 Plus. The Tandem Mobi with Control-IQ uses the same algorithm in a smaller, more compact pump body with app-based control.
The Omnipod 5 is a tubeless AID system that delivers automated adjustments every five minutes based on CGM data from a compatible Dexcom or FreeStyle Libre sensor. Its on-body pod means no tubing, and the entire system can be controlled from a smartphone app or dedicated controller.
The Medtronic MiniMed 780G with its SmartGuard algorithm delivers automatic corrections every five minutes, offers a glucose target as low as 100 mg/dL, and includes meal detection technology designed to compensate for missed or underestimated mealtime boluses. It pairs with the Guardian 4 sensor for a fully calibration-free closed-loop experience.
The Beta Bionics iLet takes a different approach from other AID systems, using a bionic pancreas algorithm that requires only the user's body weight for initialization rather than detailed insulin settings. Users announce meals as "usual," "more," or "less" rather than entering carbohydrate counts, and the system adapts its delivery over time based on each person's glucose response. A pivotal clinical trial published in the New England Journal of Medicine and covered by the NIH found the iLet significantly improved A1C and time in range compared to standard-of-care management.
Visit our Learning Center for detailed guides on each of these systems, or explore our Education page for more resources on choosing the right pump for your needs.
Why AID Matters for Everyday Life With Diabetes
Beyond the clinical outcomes data, AID systems change the texture of daily life with diabetes in ways that are hard to quantify but deeply meaningful to the people who experience them. Fewer manual adjustments, more predictable overnight glucose, less vigilance required during sleep, and more buffer when meals don't go as planned all add up to a reduction in the constant cognitive load that diabetes management demands. A psychosocial outcomes study published in PubMed Central found that parents, youth, and adults using the iLet reported decreased burden and improved freedom and flexibility, with participants describing less mental energy devoted to diabetes management as one of the most valued outcomes. That kind of real-world relief is what AID systems, at their best, deliver. At Adapt Health Diabetes, we carry the full range of AID-capable pumps and can help you verify your insurance coverage and get set up.
Frequently Asked Questions About Automated Insulin Delivery
Do I still need to do anything manually with an AID system?
Yes, in most current systems. All commercially available hybrid closed-loop AID systems require you to announce meals and manually program a mealtime bolus, typically by entering an estimated carbohydrate count. The basal insulin adjustments and automatic corrections happen without any action from you, but mealtimes still involve user input. The Beta Bionics iLet reduces this further by accepting a simple "usual," "more," or "less" meal announcement rather than requiring a carbohydrate gram count, making it the closest to hands-free of any currently approved system.
Will an AID system replace my need to monitor glucose?
AID systems work together with your CGM rather than replacing glucose awareness. In fact, your CGM becomes even more central to your management because it is the data source driving all of the system's automated decisions. You'll still want to review your glucose trends regularly, particularly after meals, during exercise, and when making changes to your routine. What you won't need to do as frequently is manually check and adjust based on those readings, because the algorithm is handling much of that response in real time.
Is an AID system appropriate for type 2 diabetes?
Several current AID systems, including the Omnipod 5, Tandem t:slim X2 with Control-IQ, and Medtronic MiniMed 780G, are FDA-approved for adults with type 2 diabetes in addition to their approvals for type 1. Clinical evidence for AID in type 2 populations is growing, and the ADA's 2025 Standards of Care support the use of insulin pump therapy in type 2 patients who are not meeting glucose targets with multiple daily injections. Insurance coverage for AID in type 2 diabetes varies, particularly under Medicare. Speak with your endocrinologist about whether AID therapy is appropriate for your situation.
How long does it take to get used to an AID system?
Most people find the first two to four weeks involve a learning curve as the algorithm adapts to your insulin needs and you build confidence in automated mode. It's normal for the first several days to feel like the system is overcorrecting or undercorrecting while it learns your patterns. Staying in automated mode through that adjustment period rather than switching back to manual mode frequently tends to lead to better outcomes faster. Your diabetes care team can provide guidance on what to expect and when to reach out if something feels off.
What happens if my CGM fails or goes offline while I'm using an AID system?
All current AID systems revert to manual or standard pump mode when CGM data is unavailable, typically delivering insulin at the last programmed basal rate rather than making automated adjustments. Most systems alert you when the CGM connection is lost. It's important to keep backup supplies, including additional sensors and a blood glucose meter, on hand so a CGM interruption doesn't leave you without any monitoring capability. Your pump's manufacturer documentation will specify exactly how the system behaves during a CGM outage.
Explore AID Systems Available Through Your Insurance
Adapt Health Diabetes carries the full range of AID-capable insulin pumps and compatible CGM supplies, verified through your insurance and delivered to your door. Browse our selection of Tandem Diabetes, Medtronic MiniMed, and Beta Bionics products, or visit our Resources page for more support. Contact our team with questions about coverage or which system might be the right fit.
This article is for educational purposes only and does not replace professional medical advice. Always consult your healthcare provider regarding insulin pump therapy, device selection, and diabetes management decisions.
Sources
- Weisman A, et al. A Systematic Review of Commercial Hybrid Closed-Loop Automated Insulin Delivery Systems. PubMed Central. 2023.
- Tauschmann M and Hovorka R. Closed Loop Insulin Delivery: Opportunities and Limitations. PubMed Central. 2024.
- Haidar A, et al. Psychosocial Impact of the Insulin-Only iLet Bionic Pancreas for Adults, Youth, and Caregivers of Youth with Type 1 Diabetes. PubMed Central. 2023.
- National Institutes of Health. Bionic Pancreas Improves Type 1 Diabetes Management Compared to Standard Insulin Delivery Methods. NIH. 2022.
